March 15, 2012 -- China’s aggressive cost-cutting of drug prices has put a cloud over the country’s pharmaceutical industry. A number of companies, announcing their 2011 full-year results, have blamed the government’s control of prices for shortfalls in revenues and profits. According to Jason Mann, MD, PhD, Head of Pharma/Healthcare for Barclays Capital in Hong Kong, China can’t expect much change in the direction of policy before the ruling Communist Party appoints a new generation of leaders later this year. More details....
